Status:
COMPLETED
Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers
Lead Sponsor:
University of Florida
Conditions:
Hypertension
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The researchers hypothesize that the impact of increasing systemic exposure to atenolol leads to increased risk for adverse metabolic effects from atenolol therapy in hypertension. This will be accomp...
Detailed Description
The current study is a sub-study of Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR - NCT00246519). The primary objective of this pharmacokinetic (PK) study is to investigate the correl...
Eligibility Criteria
Inclusion
- Subjects from PEAR who are on atenolol 100 mg once daily will be invited to participate
- Other inclusion criteria from PEAR
Exclusion
- Patients with BMI \>35 kg/m2 will be excluded
- Other exclusion criteria from PEAR
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00607347
Start Date
February 1 2008
End Date
June 1 2009
Last Update
September 20 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32610